Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study

Background: The efficacy and effectiveness of nintedanib as a first-line therapy in idiopathic pulmonary fibrosis (IPF) patients have been demonstrated by clinical trials and real-life studies. Our aim was to examine the safety profile and effectiveness of nintedanib when it is utilized as a second-...

Descripción completa

Detalles Bibliográficos
Autores principales: Vianello, Andrea, Salton, Francesco, Molena, Beatrice, Turato, Cristian, Graziani, Maria Laura, Braccioni, Fausto, Frassani, Valeria, Sella, Dino, Pretto, Paolo, Paladini, Luciana, Sukthi, Andi, Confalonieri, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074103/
https://www.ncbi.nlm.nih.gov/pubmed/32033147
http://dx.doi.org/10.3390/jcm9020422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074103/
https://www.ncbi.nlm.nih.gov/pubmed/32033147
http://dx.doi.org/10.3390/jcm9020422

Ejemplares similares